A 48-year-old woman with metabolic syndrome presents with fasting triglycerides of 480 mg/dL, total cholesterol of 280 mg/dL, and HDL cholesterol of 32 mg/dL. Clinical examination reveals eruptive xanthomas over the buttocks and extensor surfaces. Which investigation is most specific for identifying the underlying lipoprotein abnormality in this patient?

Explanation

## Investigating Severe Hypertriglyceridemia and Lipoprotein Phenotyping ### Clinical Presentation Analysis The patient presents with: - Severe hypertriglyceridemia (>400 mg/dL) - Low HDL cholesterol - Eruptive xanthomas (pathognomonic for Type III or Type IV hyperlipoproteinemia) - Metabolic syndrome features This constellation suggests a primary disturbance in **VLDL and/or chylomicron metabolism**, requiring phenotypic characterization. **Key Point:** Lipoprotein electrophoresis or ultracentrifugation is the gold standard for identifying the specific lipoprotein phenotype (Types I–V) in severe hypertriglyceridemia. ### Why Lipoprotein Electrophoresis/Ultracentrifugation? 1. **Separates lipoproteins by size and density:** - Chylomicrons (lowest density) - VLDL (very low density) - IDL (intermediate density) - LDL (low density) - HDL (high density) 2. **Identifies the phenotype:** - **Type I:** Chylomicronemia (defective lipoprotein lipase or apoC-II) - **Type II:** Elevated LDL (familial hypercholesterolemia) - **Type III:** Elevated remnants (familial dysbetalipoproteinemia) - **Type IV:** Elevated VLDL (common in metabolic syndrome) - **Type V:** Elevated VLDL + chylomicrons 3. **Guides management:** - Type I requires dietary fat restriction and fibrates - Type III responds to fibrates and niacin - Type IV managed with lifestyle + statins/fibrates **High-Yield:** Eruptive xanthomas + severe hypertriglyceridemia = **phenotype the lipoproteins** to distinguish Type III (dysbetalipoproteinemia) from Type IV (common in metabolic syndrome). The management differs significantly. ### Mnemonic for Lipoprotein Phenotypes **"VLDL-C-I"** (VLDL, Chylomicrons, Intermediate remnants): - **Type I:** ↑ Chylomicrons (defective clearance) - **Type II:** ↑ LDL (receptor defect) - **Type III:** ↑ Remnants (apoE defect) — eruptive xanthomas, palmar xanthomas - **Type IV:** ↑ VLDL (most common; metabolic syndrome) - **Type V:** ↑ VLDL + Chylomicrons (mixed) ### Why Other Investigations Are Insufficient | Investigation | Limitation | |---|---| | ApoC-II/C-III levels | Supportive but not diagnostic; does not phenotype lipoproteins | | Fasting glucose/HbA1c | Assesses glycemic control, not lipoprotein phenotype | | LFTs and amylase | Rule out secondary causes (liver disease, pancreatitis) but do not identify phenotype | **Clinical Pearl:** Eruptive xanthomas are a sign of acute, severe hypertriglyceridemia and warrant urgent phenotyping to rule out Type I (risk of acute pancreatitis) and to guide therapy. Lipoprotein electrophoresis provides this critical information.